Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 45 Breast Neoplasms 44 Precursor Cell Lymphoblastic Leukemia-Lymphoma 42 Lymphoma, Large B-Cell, Diffuse 41 Lymphoma, Non-Hodgkin 39 Multiple Myeloma 35 Leukemia 34 Melanoma 32 Leukemia, Lymphocytic, Chronic, B-Cell 32 Recurrence 31 Leukemia, Myeloid, Acute 28 Lymphoma, Follicular 27 Lymphoma, B-Cell 25 Ovarian Neoplasms 24 Lymphoma, Mantle-Cell 23 Neoplasm Metastasis 22 Hematologic Neoplasms 19 Pancreatic Neoplasms 18 Myelodysplastic Syndromes 18 Hodgkin Disease 18 Burkitt Lymphoma 16 Neoplasms 13 Carcinoma, Non-Small-Cell Lung 13 Triple Negative Breast Neoplasms 12 Lymphoma, B-Cell, Marginal Zone 12 Colorectal Neoplasms 12 Stomach Neoplasms 11 Waldenstrom Macroglobulinemia 9 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9 Carcinoma, Hepatocellular 9

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cancer Related Cognitive Decline × Cyclophosphamide × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡